[ same content as current IR page ]
At Concert Pharmaceuticals, we are pioneering our world-class expertise in deuterium chemistry to discover and develop innovative drug products that have impact for patients and address important medical needs.
Our innovative approach has already resulted in multiple drug candidates that have advanced into clinical trials. Each of these novel candidates was designed to be improved with our deuterium chemistry, and is based on an approved drug, an advanced clinical candidate or a previously studied, biologically active compound.
We apply our DCE Platform® (Deuterated Chemical Entity Platform) to design drug compounds that selectively incorporate deuterium to potentially achieve enhanced clinical safety, tolerability or efficacy in order to improve the outcomes of patients with challenging diseases. We have implemented this approach—in our own drug development and in our collaborations—to develop a robust pipeline of new medicines that offer improved ways to target a broad range of disease areas, including CNS disorders, renal disease, inflammation and cancer.